Kura Oncology surged after the FDA approved KOMZIFTI, the first once-daily oral therapy for adults with relapsed or refractory AML with an NPM1 mutation. The approval came ahead of schedule, and the drug is available immediately under Kura and Kyowa Kirin joint commercialization plan. Retail traders said Kura pipeline remains undervalued as buzz spiked on Stocktwits.